How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.
Description:
The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of Locally Advanced Pancreatic Cancer
Sponsor:
OncoSil Medical Limited
Contacts:
Henk Tissinghenk.tissing@oncosil.com
+31651384883
Tom Mahertom.maher@oncosil.com
Government Study Link:
NCT05466799 - Click here to see study onClinicalTrials.gov
